Evolve BioSystems is dedicated to developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome.
Building on a decade of expertise in the partnership between the infant gut microbiome and human breast milk, Evolve is solving newborn gut dysbiosis, or an imbalance beneficial bacteria, through microbiome-based interventions in both human and animal health.
Evolve BioSystems and the Regents of the University of California have jointly filed and served a patent infringement complaint against Abbott Laboratories.
Findings from a new study published in Pediatric Research show that feeding activated B. infantis EVC001 to breastfed infants reduced markers of chronic intestinal inflammation by up to 98 percent during a critical period of immune system development.
Breastfed infants fed activated B. infantis EVC001 experience improved metabolism of protein-bound glycans from human milk compared to matched controls.
Breakthrough Study Reveals Activated B. infantis EVC001 as the First Infant Probiotic to Be Effective in the Fight Against Antibiotic Resistance
Evolve BioSystem’s Infant Health Advisory Board aims to restore the beneficial bacteria essential to establishing a functional infant microbiome, and reduce the risk of short and long-term health challenges in infants worldwide.
Evolve BioSystems, makers of Evivo® baby probiotic, today announced that its flagship consumer product Evivo is now available in Hong Kong and Singapore.
A new study published in mSphere found that children with higher levels of the beneficial bacteria, Bifidobacterium, in their gut microbiome had reduced abundance and lower frequency of antimicrobial resistance (AMR) genes.
Evivo® infant stool test prototype is the first ever point-of-care screening test to provide a clear window into infant gut health
The beneficial bacterium found in Evivo® baby probiotic is clinically shown to support a protective intestinal environment in infants.
Evolve BioSystems, Inc. (www.evolvebiosystems.com) announced publication of a study showing that two weeks of supplementation with Bifidobacterium longum subsp. infantis EVC001 (B. infantis EVC001, currently available to consumers as Evivo® baby probiotic) in breastfed infants led to an 85 percent reduction in virulence factor genes, the tools which enable pathogens to thrive and cause infection in humans.